Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS)

被引：0
|
作者：
Fizazi, K. [1 ]
Luz, M. [2 ]
Ulys, A. [3 ]
Ortiz, J. [4 ]
Srinivasan, S. [5 ]
Kurland, E. [6 ]
Shore, N. D. [7 ]
机构：
[1] Univ Paris Saclay, Inst Gustave Roussy, Villejuif, France
[2] Hosp Erasto Gaertner, Dept Urol, Curitiba, Parana, Brazil
[3] Vilnius Univ, Inst Oncol, Vilnius, Lithuania
[4] Bayer HealthCare, Dept Med Affairs, Whippany, NJ USA
[5] Bayer HealthCare, Dept Stat, Whippany, NJ USA
[6] Bayer HealthCare, Clin Dev, Whippany, NJ USA
[7] Carolina Urol Res Ctr & Genesis Care, Dept Urol, Atlant Urol, Myrtle Beach, SC USA
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A1193
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Impact of Darolutamide on Local Symptoms in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 11 - 12
  • [32] Effects of prior local therapy by radical prostatectomy or radiotherapy on the efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer from aramis
    Saar, M.
    Fizazi, K.
    Shore, N. D.
    Smith, M. R.
    Damber, J-E
    Semenov, A.
    Ribal Caparros, M. J.
    Birtle, A.
    Rigaud, J.
    Ortiz, J.
    Schmall, A.
    Srinivasan, S.
    Verholen, F.
    EUROPEAN UROLOGY, 2022, 81 : S1423 - S1424
  • [33] Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
    Uemura, Hiroji
    Matsushima, Hisashi
    Kobayashi, Kazuki
    Mizusawa, Hiroya
    Nishimatsu, Hiroaki
    Fizazi, Karim
    Smith, Matthew
    Shore, Neal
    Tammela, Teuvo
    Tabata, Ken-ichi
    Matsubara, Nobuaki
    Iinuma, Masahiro
    Uemura, Hirotsugu
    Oya, Mototsugu
    Momma, Tetsuo
    Kawakita, Mutsushi
    Fukasawa, Satoshi
    Kobayashi, Tadahiro
    Kuss, Iris
    Le Berre, Marie-Aude
    Snapir, Amir
    Sarapohja, Toni
    Suzuki, Kazuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (03) : 578 - 590
  • [34] Efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) > and ≤ 6 months
    Schostak, Martin
    Boegemann, Martin
    Smith, Matthew R.
    Shore, Neal D.
    Tammela, Teuvo L. J.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Le Berre, Marie-Aude
    Snapir, Amir
    Sarapohja, Toni
    Fizazi, Karim
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 105 - 105
  • [35] IMPACT OF DAROLUTAMIDE ON LOCAL SYMPTOMS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Shore, Neal
    Stenzl, Arnulf
    Pieczonka, Christopher
    Klaassen, Zachary
    Aronson, William
    Karsh, Lawrence
    Ryan, Charles
    Miskic, Marina
    Srinivasan, Shankar
    Mohamed, Ateesha
    Verholen, Frank
    JOURNAL OF UROLOGY, 2021, 206 : E586 - E587
  • [36] Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
    Hiroji Uemura
    Hisashi Matsushima
    Kazuki Kobayashi
    Hiroya Mizusawa
    Hiroaki Nishimatsu
    Karim Fizazi
    Matthew Smith
    Neal Shore
    Teuvo Tammela
    Ken-ichi Tabata
    Nobuaki Matsubara
    Masahiro Iinuma
    Hirotsugu Uemura
    Mototsugu Oya
    Tetsuo Momma
    Mutsushi Kawakita
    Satoshi Fukasawa
    Tadahiro Kobayashi
    Iris Kuss
    Marie-Aude Le Berre
    Amir Snapir
    Toni Sarapohja
    Kazuhiro Suzuki
    International Journal of Clinical Oncology, 2021, 26 : 578 - 590
  • [37] Darolutamide for treatment of castration-resistant prostate cancer
    Rhea, L. P.
    Mendez-Marti, S.
    Aragon-Ching, J. B.
    DRUGS OF TODAY, 2020, 56 (03) : 185 - 193
  • [38] Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons.
    Jiang, Shan
    Terasawa, Emi
    Horton, Viviana Garcia
    Ayyagari, Rajeev
    Waldeck, A. Reginald
    Halabi, Susan
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial (vol 17, pg 1699, 2016)
    Fizazi, K.
    Blue, Ian
    Nowak, Joel T.
    FUTURE ONCOLOGY, 2021, 18 (02) : 275 - 275
  • [40] Real-world treatment patterns among veterans with nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Halwani, Ahmad Sami
    Patil, Vikas
    Morreall, Deborah
    Li, Chunyang
    Yong, Christina
    Appukkutan, Sreevalsa
    Partridge, Jamie
    Jhaveri, Jay
    Rasmussen, Kelli Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17042 - E17042
12345